

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Ragina Naidu

**Application No.:** 10/590,647

**Filed:** August 24, 2006

**Confirmation No.:** 2158

**For:** SEMI-SYNTHESIS OF TAXANE  
INTERMEDIATES AND AZIRIDINE  
ANALOGUES AND THEIR  
CONVERSION TO PACLITAXEL AND  
DOCETAXEL

**Examiner:** \_\_\_\_\_


**Art Unit:** \_\_\_\_\_

**Attorney Reference No.:** 739-76514-01

**CERTIFICATE OF MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP MISSING PARTS, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent  
for Applicant(s)



Date Mailed July 18, 2007

MAIL STOP MISSING PARTS  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicant respectfully requests that these documents be listed as references cited on the issued patent.

Applicant filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicant to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this Information Disclosure Statement is enclosed.


The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By

  
\_\_\_\_\_  
Travis Young, Ph.D.  
Registration No. 53,819

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Attorney Docket Number	739-76514-01
Application Number	10/590,647
Filing Date	August 24, 2006
First Named Inventor	Ragina Naidu
Art Unit	To be assigned
Examiner Name	To be assigned

## **U.S. PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,319,112	07 June 1994	Kingston et al.
		5,808,113	15 Sept 1998	Murray et al.

## **FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee

## **OTHER DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	
		Beckvermit et al., "An Improved Method for Separating Paclitaxel and Cephalomannine Using Ozone and Girard Reagents," <i>J. Org. Chem.</i> 61(25):9038-9040, 1996
		Commerçon et al., "Improved Protection and Esterification of a Precursor of the TAXOTERE® and Taxol Side Chains," <i>Tetrahedron Letters</i> 33(36):5185-5188, 1992
		Pines et al., "The Stereochemistry of 2,3-Diphenyl-1-methylpropylamine," <i>Journal of Medical Chemistry</i> 10(4):725-728, 1967
		Rimoldi et al., "An Improved Method for the Separation of Paclitaxel and Cephalomannine," <i>Journal of Natural Products</i> 59(2):167-168, 1996

EXAMINER  
SIGNATURE:

DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.